Medicenna Therapeutics (TSE:MDNA) Trading Down 1.7% – Here’s What Happened

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price traded down 1.7% during trading on Monday . The stock traded as low as C$1.06 and last traded at C$1.13. 72,877 shares changed hands during mid-day trading, an increase of 2% from the average session volume of 71,481 shares. The stock had previously closed at C$1.15.

Medicenna Therapeutics Price Performance

The firm has a 50-day simple moving average of C$1.43 and a two-hundred day simple moving average of C$1.84. The company has a market capitalization of C$84.54 million, a price-to-earnings ratio of -3.11 and a beta of 1.21. The company has a current ratio of 11.40, a quick ratio of 4.65 and a debt-to-equity ratio of 0.88.

Insider Transactions at Medicenna Therapeutics

In other news, Senior Officer David Hyman bought 20,000 shares of the business’s stock in a transaction dated Thursday, January 9th. The stock was purchased at an average cost of C$1.45 per share, with a total value of C$29,000.00. Company insiders own 22.57% of the company’s stock.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.